Alpha Cognition Reports Top-Line Results From BEACON Real-World Study Of ZUNVEYL

Alpha Cognition Inc

Alpha Cognition Inc

ACOG

0.00

 

  • Providers reported cognitive improvement in 92% of patients following initiation of ZUNVEYL
  • Providers reported improvement in neuropsychiatric symptoms in 93% of patients after initiation of ZUNVEYL
  • Providers reported delayed initiation or discontinuation of concomitant psychotropic medications in 80% of patients receiving ZUNVEYL
  • Providers reported favorable changes in activities of daily living (ADLs) in 71% of patients following initiation of ZUNVEYL
  • Providers reported improvements across sleep-related outcomes in 72% of patients following initiation of ZUNVEYL
  • Providers reported favorable gastrointestinal (GI) tolerability and overall treatment experience in patients receiving ZUNVEYL
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.